|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
101,390,000 |
Market
Cap: |
1.55(B) |
Last
Volume: |
668,805 |
Avg
Vol: |
666,939 |
52
Week Range: |
$11.44 - $16.78 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
661,000 |
664,000 |
Total Buy Value |
$0 |
$0 |
$8,435,402 |
$8,468,005 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
11 |
12 |
Total Shares Sold |
0 |
10,994 |
10,994 |
10,994 |
Total Sell Value |
$0 |
$153,810 |
$153,810 |
$153,810 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
1 |
1 |
1 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Zhen Marianne |
Chief Accounting Officer |
|
2020-02-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
8,741 |
30,654 |
|
- |
|
Hulme Geoffrey |
Interim Principal Exec Officer |
|
2020-02-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
15,734 |
45,469 |
|
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-11-20 |
4 |
D |
$12.59 |
$7,579 |
D/D |
(602) |
26,940 |
|
- |
|
Hulme Geoffrey |
Interim PEO |
|
2019-09-04 |
4 |
A |
$10.89 |
$32,684 |
D/D |
3,000 |
31,000 |
|
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-08-20 |
4 |
D |
$11.50 |
$6,900 |
D/D |
(600) |
27,542 |
|
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-05-20 |
4 |
D |
$14.21 |
$8,540 |
D/D |
(601) |
28,142 |
|
- |
|
Dipaolo Mark |
Director |
|
2019-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,399 |
41,165 |
|
- |
|
Schlesinger Sarah J. |
Director |
|
2019-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,399 |
41,165 |
|
- |
|
Haimovitz Jules |
Director |
|
2019-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,399 |
53,365 |
|
- |
|
Bickerstaff George |
Director |
|
2019-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,399 |
70,161 |
|
- |
|
Kostas Odysseas D |
Director |
|
2019-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,399 |
45,161 |
|
- |
|
Hulme Geoffrey |
Interim PEO |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,677 |
27,584 |
|
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,154 |
26,818 |
|
- |
|
Bickerstaff George |
Director |
|
2019-02-27 |
4 |
B |
$15.90 |
$238,500 |
D/D |
15,000 |
53,762 |
2.39 |
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-02-26 |
4 |
S |
$16.00 |
$89,872 |
D/D |
(5,617) |
18,664 |
|
- |
|
Bickerstaff George |
Director |
|
2019-02-21 |
4 |
B |
$14.90 |
$148,958 |
D/D |
10,000 |
38,762 |
2.39 |
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2019-02-20 |
4 |
D |
$14.67 |
$19,849 |
D/D |
(1,353) |
24,281 |
|
- |
|
Hulme Geoffrey |
Interim PEO |
|
2019-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
16,000 |
|
- |
|
Hulme Geoffrey |
Interim PEO |
|
2019-02-19 |
4/A |
D |
$14.53 |
$44,941 |
D/D |
(3,093) |
12,907 |
|
- |
|
Hulme Geoffrey |
Interim PEO |
|
2019-02-15 |
4 |
B |
$14.80 |
$103,600 |
D/D |
7,000 |
7,000 |
2.74 |
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2018-11-20 |
4 |
D |
$16.43 |
$8,872 |
D/D |
(540) |
25,634 |
|
- |
|
Zhen Marianne |
Chief Accounting Officer |
|
2018-09-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,779 |
23,347 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2018-08-21 |
4 |
S |
$14.12 |
$120,080 |
D/D |
(8,504) |
247,767 |
|
- |
|
Abercrombie George B |
Sr. VP & Chief Comm. Officer |
|
2018-08-21 |
4 |
AS |
$14.11 |
$112,840 |
D/D |
(8,000) |
285,479 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2018-08-20 |
4 |
D |
$14.08 |
$43,493 |
D/D |
(3,089) |
256,271 |
|
- |
|
283 Records found
|
|
Page 4 of 12 |
|
|